452 related articles for article (PubMed ID: 16391791)
21. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Karikó K; Kuo A; Boyd D; Okada SS; Cines DB; Barnathan ES
Cancer Res; 1993 Jul; 53(13):3109-17. PubMed ID: 8391387
[TBL] [Abstract][Full Text] [Related]
22. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Fujiuchi Y; Nagakawa O; Murakami K; Fuse H; Saiki I
Oncol Rep; 2003; 10(4):1001-6. PubMed ID: 12792760
[TBL] [Abstract][Full Text] [Related]
23. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Shiratsuchi T; Ishibashi H; Shirasuna K
J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986
[TBL] [Abstract][Full Text] [Related]
25. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
26. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
27. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Lakka SS; Rajagopal R; Rajan MK; Mohan PM; Adachi Y; Dinh DH; Olivero WC; Gujrati M; Ali-Osman F; Roth JA; Yung WK; Kyritsis AP; Rao JS
Clin Cancer Res; 2001 Apr; 7(4):1087-93. PubMed ID: 11309361
[TBL] [Abstract][Full Text] [Related]
29. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Inuzuka K; Ogata Y; Nagase H; Shirouzu K
J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
[TBL] [Abstract][Full Text] [Related]
30. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
31. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
32. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
de Bock CE; Lin Z; Itoh T; Morris D; Murrell G; Wang Y
FEBS J; 2005 Jul; 272(14):3572-82. PubMed ID: 16008557
[TBL] [Abstract][Full Text] [Related]
34. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
35. Expression and activation of proteases in co-cultures.
Paduch R; Kandefer-Szerszeń M
Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
37. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
40. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons.
Wu MH; Hong TM; Cheng HW; Pan SH; Liang YR; Hong HC; Chiang WF; Wong TY; Shieh DB; Shiau AL; Jin YT; Chen YL
Mol Cancer Res; 2009 Mar; 7(3):311-8. PubMed ID: 19276182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
